Target
Information |
Name | mRNA of sodium-glucose transporter-2 |
Type of target | Clinical trial target |
Synonyms | mRNA of Low affinity sodium-glucose cotransporter |
mRNA of Na(+)/glucose cotransporter 2 |
mRNA of SGLT2 |
mRNA of SLC5A2 |
mRNA of Sodium/glucose cotransporter 2 |
mRNA of Solute carrier family 5 member 2 |
Disease | Type 2 Diabetes [ICD9: 250.00, 250.02 ICD10: E11] | [1] |
Drug(s) | ISIS-SGLT2 |  | Phase I | Type 2 Diabetes | [1] |
UniProt ID | P31639 |
Function | Sodium-dependent glucose transporter. Has a Na(+) to glucose coupling ratio of 1:1.Efficient substrate transport in mammalian kidney is provided by the concerted action of a low affinity high capacity and a high affinity low capacity Na(+)/glucose cotransporter arranged in series along kidney proximal tubules. |
Sequence | MEEHTEAGSAPEMGAQKALIDNPADILVIAAYFLLVIGVGLWSMCRTNRGTVGGYFLAGR
SMVWWPVGASLFASNIGSGHFVGLAGTGAASGLAVAGFEWNALFVVLLLGWLFAPVYLTA
GVITMPQYLRKRFGGRRIRLYLSVLSLFLYIFTKISVDMFSGAVFIQQALGWNIYASVIA
LLGITMIYTVTGGLAALMYTDTVQTFVILGGACILMGYAFHEVGGYSGLFDKYLGAATSL
TVSEDPAVGNISSFCYRPRPDSYHLLRHPVTGDLPWPALLLGLTIVSGWYWCSDQVIVQR
CLAGKSLTHIKAGCILCGYLKLTPMFLMVMPGMISRILYPDEVACVVPEVCRRVCGTEVG
CSNIAYPRLVVKLMPNGLRGLMLAVMLAALMSSLASIFNSSSTLFTMDIYTRLRPRAGDR
ELLLVGRLWVVFIVVVSVAWLPVVQAAQGGQLFDYIQAVSSYLAPPVSAVFVLALFVPRV
NEQGAFWGLIGGLLMGLARLIPEFSFGSGSCVQPSACPAFLCGVHYLYFAIVLFFCSGLL
TLTVSLCTAPIPRKHLHRLVFSLRHSKEEREDLDADEQQGSSLPVQNGCPESAMEMNEPQ
APAPSLFRQCLLWFCGMSRGGVGSPPPLTQEEAAAAARRLEDISEDPSWARVVNLNALLM
MAVAVFLWGFYA
|
Target Validation | Click to Find Target Validation Information. |
Inhibitor | 10-methoxy-N (1)-methylburnamine-17-O-veratrate |  | [2] |
ACEROGENIN B |  | [3] |
Alstiphyllanine D |  | [2] |
Alstiphyllanine E |  | [2] |
Alstiphyllanine F |  | [2] |
Burnamine-17-O-3',4',5'-trimethoxybenzoate |  | [2] |
FORMONONETIN |  | [4] |
KURAIDIN |  | [4] |
KURARINONE |  | [4] |
MAACKIAIN |  | [4] |
O-spiroketal glucoside |  | [5] |
PHLORIZIN |  | [6] |
SERGLIFLOZIN A |  | [7] |
acerogenin C |  | [3] |
kushenol N |  | [4] |
remogliflozin |  | [8] |
sophoraflavanone G |  | [4] |
Antisense | ISIS-SGLT2 |  | [1] |
Cross References |
3D Structure
Related Literature
On-Line
Medical Dictionary |
Ref 1 | 2011 Pipeline of ISIS Pharm. To Reference |
Ref 2 | Bioorg Med Chem. 2010 Mar 15;18(6):2152-8. Epub 2010 Feb 6.Alstiphyllanines E-H, picraline and ajmaline-type alkaloids from Alstonia macrophylla inhibiting sodium glucose cotransporter. To Reference |
Ref 3 | Bioorg Med Chem Lett. 2010 Feb 1;20(3):1070-4. Epub 2009 Dec 11.Cyclic diarylheptanoids as Na+-glucose cotransporter (SGLT) inhibitors from Acer nikoense. To Reference |
Ref 4 | Bioorg Med Chem. 2007 May 15;15(10):3445-9. Epub 2007 Mar 12.Na+-glucose cotransporter (SGLT) inhibitory flavonoids from the roots of Sophora flavescens. To Reference |
Ref 5 | Bioorg Med Chem. 2010 Jun 15;18(12):4422-32. Epub 2010 Apr 29.ortho-Substituted C-aryl glucosides as highly potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors. To Reference |
Ref 6 | J Med Chem. 2010 Apr 22;53(8):3247-61.(1S)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucitol (TS-071) is a potent, selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for type 2 diabetes treatment. To Reference |
Ref 7 | Bioorg Med Chem. 2010 Mar 15;18(6):2178-94. Epub 2010 Feb 4.Novel C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents: 1,3,4-Thiadiazolylmethylphenyl glucoside congeners. To Reference |
Ref 8 | J Med Chem. 2009 Apr 9;52(7):1785-94.Development of the renal glucose reabsorption inhibitors: a new mechanism for the pharmacotherapy of diabetes mellitus type 2. To Reference |